ALBI grade predicts suitability for further systemic therapy following sorafenib in patients with advanced hepatocellular carcinoma
- Resource Type
- Source
- Liver Cancer International. 4:5-12
- Subject
Complementary and alternative medicine Pharmaceutical Science Pharmacology (medical) - Language
- ISSN
- 2642-3561